Pfizer Inc. (PFE) reported $63.63B of revenue for the twelve months ended Sep 27, 2026. That is up 1.3% from the year before. Revenue for fiscal 2025 was $62.58B.

Yes. Pfizer Inc. earned $4.03B in net income for the twelve months ended Sep 27, 2026, a net margin of 6.3%.

How much cash and debt does PFE have?

Pfizer Inc. reported $1.82B in cash and cash equivalents and $62.67B of debt on its most recent balance sheet in SEC filings.

How fast is PFE revenue growing?

Pfizer Inc.'s revenue changed -1.6% in fiscal 2025, to $62.58B. Its compound annual growth rate was +8.5% over 5 years.

What is PFE gross margin?

Pfizer Inc.'s gross profit was $46.69B on $63.63B of revenue for the twelve months ended Sep 27, 2026, a gross margin of 73.4%.

What is PFE free cash flow?

Pfizer Inc. generated $11.79B of free cash flow for the twelve months ended Sep 27, 2026, which is operating cash flow of $14.17B less capital expenditures.

What is PFE earnings per share?

Diluted earnings per share were $0.70 for the twelve months ended Sep 27, 2026, from SEC filings, restated for any stock split those filings show.

When did PFE last report financial results?

The latest statements here come from Pfizer Inc.'s 10-Q filed on Nov 3, 2026, covering the period ended Sep 27, 2026.

Where does this PFE financial data come from?

Quantisnow builds these statements from the structured XBRL data Pfizer Inc. files with the SEC. It is provided for information only and is not investment advice.

Financials · PFE

Pfizer Inc. (PFE) financials

For the twelve months ended Sep 27, 2026, Pfizer Inc. reported $63.63B of revenue and $4.03B of net income.

Revenue, TTM: $63.63B
Revenue growth, YoY: +1.3%
Net income, TTM: $4.03B
Net income growth, YoY: -59.0%
Net margin: 6.3%
Free cash flow, TTM: $11.79B
EPS, diluted, TTM: $0.70
EPS growth, YoY: -59.3%
Cash: $1.82B
Total debt: $62.67B
P/E: 41.53
P/S: 2.63
Market cap: $167.49B

Annual revenue$62.58B

FY2016FY2025

Annual net income$7.77B

FY2016FY2025

Annual free cash flow$9.07B

FY2016FY2025

PFE revenue and earnings growth

PFE revenueQ3 2026$16.58B

Quarter YoY: -0.4%
QoQ: +10.3%
FY YoY: -1.6%
5Y CAGR: +8.5%

PFE revenue was $16.58B in fiscal Q3 2026 (ended Sep 27, 2026), down 0.4% from a year earlier and up 10.3% from the prior quarter. For the full fiscal 2025 it was $62.58B, down 1.6% from fiscal 2024. Compound annual growth was +8.5% over 5 years. It rose in 5 of the last 9 fiscal years.

PFE net incomeQ3 2026$3.24B

Quarter YoY: -8.4%
FY YoY: -3.2%
5Y CAGR: -3.2%
10Y CAGR: +1.1%

PFE net income was $3.24B in fiscal Q3 2026 (ended Sep 27, 2026), down 8.4% from a year earlier. For the full fiscal 2025 it was $7.77B, down 3.2% from fiscal 2024. Compound annual growth was -3.2% over 5 years and +1.1% over 10 years. It rose in 6 of the last 10 fiscal years.

PFE EPSQ3 2026$0.56

Quarter YoY: -9.7%
FY YoY: -3.5%
5Y CAGR: -3.6%
10Y CAGR: +2.1%

PFE diluted EPS was $0.56 in fiscal Q3 2026 (ended Sep 27, 2026), down 9.7% from a year earlier. For the full fiscal 2025 it was $1.36, down 3.5% from fiscal 2024. Compound annual growth was -3.6% over 5 years and +2.1% over 10 years.

PFE free cash flowQ3 2026$4.80B

Quarter YoY: +20.0%
QoQ: 16x
FY YoY: -7.7%
5Y CAGR: -5.7%
10Y CAGR: -3.7%

PFE free cash flow was $4.80B in fiscal Q3 2026 (ended Sep 27, 2026), up 20.0% from a year earlier and up about 16-fold from the prior quarter. For the full fiscal 2025 it was $9.07B, down 7.7% from fiscal 2024. Compound annual growth was -5.7% over 5 years and -3.7% over 10 years. It rose in 5 of the last 10 fiscal years.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue	$62.58B	$63.63B	$59.55B	$101.17B	$81.29B	$41.65B	$40.91B	$40.83B	$52.55B	$52.82B
Cost of revenue	$16.07B	$17.85B	$24.95B	$34.34B	$30.82B	$8.48B	$8.05B	$8.99B	$11.23B	$12.32B
Gross profit	$46.51B	$45.78B	$34.60B	$66.83B	$50.47B	$33.17B	$32.85B	$31.84B	$41.32B	$40.50B
Research and development	$10.44B	$10.82B	$10.68B	$11.43B	$10.36B	$8.71B	$8.38B	$7.76B	$7.68B	$7.89B
Selling, general and admin	$13.79B	$14.73B	$14.77B	$13.68B	$12.70B	$11.60B	$12.73B	$12.61B	$14.80B	$14.84B
Interest expense	$2.67B	$3.09B	$2.21B	$1.24B	$1.29B	$1.45B	$1.57B	$1.32B	$1.27B	$1.19B
Pre-tax income	$7.52B	$8.02B	$1.06B	$34.73B	$24.31B	$7.04B	$11.32B	$3.59B	$12.30B	$8.35B
Income tax	-$266.00M	-$28.00M	-$1.11B	$3.33B	$1.85B	$370.00M	$583.00M	-$266.00M	-$9.05B	$1.12B
Net income	$7.77B	$8.03B	$2.12B	$31.37B	$21.98B	$9.16B	$16.03B	$11.15B	$21.31B	$7.21B
EPS, basic	$1.37	$1.42	$0.38	$5.59	$3.92	$1.65	$2.88	$1.90	$3.57	$1.18
EPS, diluted	$1.36	$1.41	$0.37	$5.47	$3.85	$1.63	$2.82	$1.87	$3.52	$1.17
Diluted shares	5.71B	5.70B	5.71B	5.73B	5.71B	5.63B	5.67B	5.98B	6.06B	6.16B

Balance sheet

Balance sheet
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Cash and equivalents	$1.14B	$1.11B	$2.92B	$468.00M	$1.98B	$1.82B	$1.35B	$1.23B	$1.43B	$2.67B
Short-term investments	-	-	-	-	-	$10.44B	$8.53B	$17.69B	$18.65B	$15.26B
Receivables	$11.87B	$11.46B	$11.57B	$10.95B	$11.48B	$7.91B	$6.77B	$8.03B	$8.22B	$8.22B
Inventory	$10.65B	$10.85B	$10.19B	$8.98B	$9.06B	$8.02B	$7.07B	$7.51B	$7.58B	$6.78B
Current assets	$42.90B	$50.36B	$43.33B	$51.26B	$59.69B	$35.07B	$32.80B	$49.93B	$41.14B	$38.95B
Goodwill	$71.26B	$68.53B	$67.78B	$51.38B	$49.21B	$49.56B	$48.18B	$42.93B	$55.95B	$54.45B
Total assets	$208.16B	$213.40B	$226.50B	$197.21B	$181.48B	$154.23B	$167.59B	$159.42B	$171.80B	$171.62B
Current liabilities	$36.98B	$42.99B	$47.79B	$42.14B	$42.67B	$25.92B	$37.30B	$31.86B	$30.43B	$31.11B
Short-term debt	$3.15B	$6.95B	$10.35B	$2.94B	$2.24B	$2.70B	$16.20B	$8.83B	$9.95B	$10.69B
Long-term debt	$61.64B	$57.41B	$61.54B	$32.88B	$36.20B	$37.13B	$35.95B	$32.91B	$33.54B	$31.40B
Total debt	$64.80B	$64.35B	$71.89B	$35.83B	$38.44B	$39.84B	$52.15B	$41.74B	$43.49B	$42.09B
Total liabilities	$121.39B	$124.90B	$137.21B	$101.29B	$104.01B	$90.76B	$104.15B	$95.66B	$100.14B	$111.78B
Shareholders' equity	$86.48B	$88.50B	$89.29B	$95.92B	$77.46B	$63.47B	$63.45B	$63.76B	$71.66B	$59.84B

Cash flow

Cash flow
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Operating cash flow	$11.70B	$12.74B	$8.70B	$29.27B	$32.58B	$14.40B	$12.59B	$15.83B	$16.80B	$16.19B
Capital expenditures	$2.63B	$2.91B	$3.91B	$3.24B	$2.71B	$2.23B	$2.05B	$1.98B	$1.96B	$1.82B
Free cash flow	$9.07B	$9.84B	$4.79B	$26.03B	$29.87B	$12.18B	$10.54B	$13.84B	$14.85B	$14.37B
Investing cash flow	-$1.35B	$2.65B	-$32.28B	-$15.78B	-$22.55B	-$4.27B	-$3.94B	$4.53B	-$4.74B	-$7.79B
Financing cash flow	-$10.30B	-$17.14B	$26.07B	-$14.83B	-$9.82B	-$9.65B	-$8.48B	-$20.44B	-$13.35B	-$9.23B
Share repurchases	-	$0	$0	$2.00B	$0	$0	$8.87B	$12.20B	$5.00B	$5.00B
Stock-based compensation	$799.00M	$877.00M	$525.00M	$872.00M	$1.18B	$755.00M	$687.00M	$923.00M	$840.00M	$691.00M
Depreciation and amortization	$6.59B	$7.01B	$6.29B	$5.06B	$5.19B	$4.68B	$5.75B	$6.38B	$6.27B	$5.76B

Key ratios

Key ratios
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue growth, YoY	-1.6%	6.8%	-41.1%	24.5%	95.2%	1.8%	0.2%	-22.3%	-0.5%	-
Net income growth, YoY	-3.2%	279.0%	-93.2%	42.7%	140.0%	-42.8%	43.7%	-47.7%	195.3%	3.7%
EPS growth, YoY	-3.5%	281.1%	-93.2%	42.1%	136.2%	-42.2%	50.8%	-46.9%	200.9%	5.4%
Gross margin	74.3%	71.9%	58.1%	66.1%	62.1%	79.6%	80.3%	78.0%	78.6%	76.7%
Net margin	12.4%	12.6%	3.6%	31.0%	27.0%	22.0%	39.2%	27.3%	40.6%	13.7%
Free cash flow margin	14.5%	15.5%	8.0%	25.7%	36.7%	29.2%	25.8%	33.9%	28.3%	27.2%
Return on equity	9.0%	9.1%	2.4%	32.7%	28.4%	14.4%	25.3%	17.5%	29.7%	12.1%
Return on assets	3.7%	3.8%	0.9%	15.9%	12.1%	5.9%	9.6%	7.0%	12.4%	4.2%
Current ratio	1.16	1.17	0.91	1.22	1.40	1.35	0.88	1.57	1.35	1.25
Debt to equity	0.75	0.73	0.81	0.37	0.50	0.63	0.82	0.65	0.61	0.70

Income statement

Income statement
Line item	Q3 2026 Sep 27, 2026	Q2 2026 Jun 28, 2026	Q1 2026 Mar 29, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 28, 2025	Q2 2025 Jun 29, 2025	Q1 2025 Mar 30, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 29, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue	$16.58B	$15.03B	$14.45B	$17.56B	$16.65B	$14.65B	$13.71B	$17.76B	$17.70B	$13.28B	$14.88B	$14.57B
Cost of revenue	$4.03B	$4.09B	$3.55B	$5.27B	$4.17B	$3.78B	$2.85B	$5.91B	$5.26B	$3.30B	$3.38B	$7.56B
Gross profit	$12.55B	$10.94B	$10.90B	$12.29B	$12.48B	$10.88B	$10.87B	$11.85B	$12.44B	$9.98B	$11.50B	$7.01B
Research and development	$3.02B	$2.81B	$2.49B	$3.21B	$2.55B	$2.48B	$2.20B	$3.04B	$2.60B	$2.70B	$2.49B	$2.81B
Selling, general and admin	$3.28B	$3.41B	$2.96B	$4.16B	$3.19B	$3.42B	$3.03B	$4.27B	$3.24B	$3.72B	$3.50B	$4.58B
Interest expense	$662.00M	$667.00M	$668.00M	$711.00M	$652.00M	$654.00M	$654.00M	$739.00M	$783.00M	$778.00M	$790.00M	$688.00M
Pre-tax income	$3.38B	-$653.00M	$3.17B	-$1.64B	$3.33B	$3.04B	$2.79B	-$10.00M	$4.71B	-$103.00M	$3.42B	-$4.13B
Income tax	$134.00M	-$407.00M	$461.00M	-$2.00M	-$216.00M	$141.00M	-$189.00M	-$421.00M	$234.00M	-$134.00M	$293.00M	-$795.00M
Net income	$3.24B	-$248.00M	$2.69B	-$1.65B	$3.54B	$2.91B	$2.97B	$410.00M	$4.46B	$41.00M	$3.12B	-$3.37B
EPS, basic	$0.57	-$0.04	$0.47	-$0.28	$0.62	$0.51	$0.52	$0.07	$0.79	$0.01	$0.55	-$0.59
EPS, diluted	$0.56	-$0.04	$0.47	-$0.29	$0.62	$0.51	$0.52	$0.07	$0.78	$0.01	$0.55	-$0.59
Diluted shares	5.75B	5.70B	5.73B	-	5.71B	5.71B	5.71B	-	5.71B	5.70B	5.70B	-

Balance sheet

Balance sheet
Line item	Q3 2026 Sep 27, 2026	Q2 2026 Jun 28, 2026	Q1 2026 Mar 29, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 28, 2025	Q2 2025 Jun 29, 2025	Q1 2025 Mar 30, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 29, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Cash and equivalents	$1.82B	$976.00M	$1.70B	$1.14B	$1.39B	$1.69B	$1.48B	$1.11B	$1.15B	$1.12B	$780.00M	$2.92B
Receivables	$14.19B	$12.49B	$12.59B	$11.87B	$14.26B	$12.08B	$11.85B	$11.46B	$14.45B	$11.39B	$10.99B	$11.57B
Inventory	$10.02B	$9.95B	$10.67B	$10.65B	$11.47B	$11.67B	$10.85B	$10.85B	$11.72B	$11.45B	$10.89B	$10.19B
Current assets	$45.01B	$41.36B	$42.82B	$42.90B	$46.92B	$43.70B	$45.86B	$50.36B	$43.22B	$37.83B	$42.41B	$43.33B
Goodwill	$71.46B	$71.42B	$71.41B	$71.26B	$69.10B	$69.00B	$68.44B	$68.53B	$68.57B	$68.44B	$69.30B	$67.78B
Total assets	$204.54B	$201.13B	$207.62B	$208.16B	$208.73B	$206.09B	$208.03B	$213.40B	$219.48B	$216.19B	$221.09B	$226.50B
Current liabilities	$31.73B	$32.65B	$34.35B	$36.98B	$36.60B	$37.73B	$36.45B	$42.99B	$43.21B	$43.82B	$40.50B	$47.79B
Short-term debt	$2.67B	$2.70B	$3.89B	$3.15B	$4.30B	$4.29B	$4.47B	$6.95B	$9.70B	$11.94B	$8.23B	$10.35B
Long-term debt	$60.00B	$60.49B	$60.56B	$61.64B	$57.41B	$57.50B	$57.64B	$57.41B	$58.00B	$57.51B	$61.31B	$61.54B
Total debt	$62.67B	$63.19B	$64.45B	$64.80B	$61.71B	$61.80B	$62.11B	$64.35B	$67.70B	$69.45B	$69.54B	$71.89B
Total liabilities	$115.24B	$115.64B	$117.21B	$121.39B	$115.64B	$117.08B	$117.39B	$124.90B	$126.92B	$128.22B	$128.54B	$137.21B
Shareholders' equity	$89.00B	$85.49B	$90.40B	$86.48B	$93.10B	$89.01B	$90.64B	$88.50B	$92.56B	$87.97B	$92.56B	$89.29B

Cash flow

Cash flow
Line item	Q3 2026 Sep 27, 2026	Q2 2026 Jun 28, 2026	Q1 2026 Mar 29, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 28, 2025	Q2 2025 Jun 29, 2025	Q1 2025 Mar 30, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 29, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Operating cash flow	$5.38B	$835.00M	$2.62B	$5.35B	$4.60B	-$582.00M	$2.33B	$6.72B	$6.71B	-$1.78B	$1.09B	$5.24B
Capital expenditures	$573.00M	$533.00M	$436.00M	$845.00M	$602.00M	$618.00M	$564.00M	$917.00M	$651.00M	$637.00M	$704.00M	$1.04B
Free cash flow	$4.80B	$302.00M	$2.18B	$4.50B	$4.00B	-$1.20B	$1.77B	$5.80B	$6.06B	-$2.42B	$386.00M	$4.20B
Investing cash flow	-$2.03B	$2.11B	$785.00M	-$6.15B	-$2.43B	$3.95B	$3.27B	-$1.62B	-$2.06B	$4.60B	$1.73B	-$11.00B
Financing cash flow	-$2.51B	-$3.66B	-$2.86B	$596.00M	-$2.48B	-$3.20B	-$5.23B	-$5.11B	-$4.64B	-$2.46B	-$4.93B	$5.44B
Share repurchases	-	-	-	-	-	-	-	-	-	-	-	$0
Stock-based compensation	$362.00M	$249.00M	$272.00M	$225.00M	$201.00M	$203.00M	$170.00M	$177.00M	$274.00M	$206.00M	$220.00M	$121.00M
Depreciation and amortization	$1.58B	$1.62B	$1.61B	$1.69B	$1.66B	$1.63B	$1.62B	$1.79B	$1.75B	$1.73B	$1.74B	$1.67B

Key ratios

Key ratios
Line item	Q3 2026 Sep 27, 2026	Q2 2026 Jun 28, 2026	Q1 2026 Mar 29, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 28, 2025	Q2 2025 Jun 29, 2025	Q1 2025 Mar 30, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 29, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue growth, YoY	-0.4%	2.6%	5.4%	-1.2%	-5.9%	10.3%	-7.8%	21.9%	31.2%	2.1%	-19.5%	-42.0%
Net income growth, YoY	-8.4%	-	-9.4%	-	-20.7%	6997.6%	-4.8%	-	-	-98.2%	-43.8%	-
EPS growth, YoY	-9.7%	-	-9.6%	-	-20.5%	5000.0%	-5.5%	-	-	-97.6%	-43.3%	-
Gross margin	75.7%	72.8%	75.4%	70.0%	74.9%	74.2%	79.3%	66.7%	70.3%	75.2%	77.3%	48.1%
Net margin	19.6%	-1.6%	18.6%	-9.4%	21.3%	19.9%	21.6%	2.3%	25.2%	0.3%	20.9%	-23.1%
Free cash flow margin	29.0%	2.0%	15.1%	25.6%	24.0%	-8.2%	12.9%	32.7%	34.3%	-18.2%	2.6%	28.8%
Current ratio	1.42	1.27	1.25	1.16	1.28	1.16	1.26	1.17	1.00	0.86	1.05	0.91
Debt to equity	0.70	0.74	0.71	0.75	0.66	0.69	0.69	0.73	0.73	0.79	0.75	0.81

Source: XBRL data Pfizer Inc. files with the SEC, latest filing dated Nov 3, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

PFE peers

Company	Revenue	Growth	Net income	Net margin	Market cap
PFE	$63.63B	+1.3%	$4.03B	6.3%	$167.49B
JNJJohnson & Johnson	$99.33B	+7.8%	$16.09B	16.2%	$664.95B
MRKMerck & Company Inc.	$67.38B	+4.9%	$2.45B	3.6%	$361.71B
NVSNovartis AG	$54.53B	+8.4%	$13.98B	25.6%	$310.17B
AZNAstraZeneca PLC	$58.74B	+8.6%	$10.22B	17.4%	$289.10B
SNYSanofi	€43.63B	+6.2%	€7.81B	17.9%	$114.71B
GSKGSK plc	£32.67B	+4.1%	£5.72B	17.5%	$101.80B
MRNAModerna Inc.	$2.23B	-27.6%	-$3.15B	-141.4%	$101.48B

PFE FAQ

9 questions

What is PFE revenue?
Pfizer Inc. (PFE) reported $63.63B of revenue for the twelve months ended Sep 27, 2026. That is up 1.3% from the year before. Revenue for fiscal 2025 was $62.58B.
Is PFE profitable?
Yes. Pfizer Inc. earned $4.03B in net income for the twelve months ended Sep 27, 2026, a net margin of 6.3%.
How much cash and debt does PFE have?
Pfizer Inc. reported $1.82B in cash and cash equivalents and $62.67B of debt on its most recent balance sheet in SEC filings.
How fast is PFE revenue growing?
Pfizer Inc.'s revenue changed -1.6% in fiscal 2025, to $62.58B. Its compound annual growth rate was +8.5% over 5 years.
What is PFE gross margin?
Pfizer Inc.'s gross profit was $46.69B on $63.63B of revenue for the twelve months ended Sep 27, 2026, a gross margin of 73.4%.
What is PFE free cash flow?
Pfizer Inc. generated $11.79B of free cash flow for the twelve months ended Sep 27, 2026, which is operating cash flow of $14.17B less capital expenditures.
What is PFE earnings per share?
Diluted earnings per share were $0.70 for the twelve months ended Sep 27, 2026, from SEC filings, restated for any stock split those filings show.
When did PFE last report financial results?
The latest statements here come from Pfizer Inc.'s 10-Q filed on Nov 3, 2026, covering the period ended Sep 27, 2026.
Where does this PFE financial data come from?
Quantisnow builds these statements from the structured XBRL data Pfizer Inc. files with the SEC. It is provided for information only and is not investment advice.